CA
NZ
UK
AU
IND
US
…
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -110.27M | -80.67M | -97.10M | -159.34M | -15.07M |
| Net income | -108.03M | -78.73M | -87.97M | -144.25M | -8.35M |
| Selling general administrative | 273.34M | 225.87M | 209.12M | 243.36M | 221.35M |
| Selling and marketing expenses | 92.01M | 84.62M | 70.84M | 67.32M | 62.59M |
| Gross profit | 282.54M | 290.10M | 244.60M | 187.90M | 187.06M |
| Reconciled depreciation | 67.82M | 72.55M | 72.58M | 69.43M | 53.35M |
| Ebit | -106.52M | -74.06M | -90.19M | -153.11M | -9.99M |
| Ebitda | -38.69M | -1.51M | -17.61M | -83.89M | 43.36M |
| Depreciation and amortization | 67.82M | 72.55M | 72.58M | 69.22M | 53.35M |
| Non operating income net other | - | - | - | -0.21M | -0.50M |
| Operating income | -66.08M | -92.11M | -107.74M | -153.11M | -9.99M |
| Other operating expenses | 793.41M | 752.67M | 699.38M | 662.84M | 603.08M |
| Interest expense | 3.75M | 6.62M | 6.91M | 1.51M | 5.08M |
| Tax provision | -2.24M | -1.95M | -9.13M | -15.09M | -6.73M |
| Interest income | 9.07M | 18.43M | 16.90M | - | - |
| Net interest income | 5.32M | 11.81M | 9.99M | -1.51M | -5.08M |
| Non recurring | - | - | - | 4.52M | - |
| Income tax expense | -2.24M | -1.95M | -9.13M | -15.09M | -6.73M |
| Total revenue | 727.33M | 660.57M | 591.64M | 509.73M | 484.33M |
| Total operating expenses | 348.62M | 382.21M | 352.34M | 341.00M | 305.81M |
| Cost of revenue | 444.79M | 370.47M | 347.04M | 321.83M | 297.27M |
| Total other income expense net | -44.19M | 11.43M | 10.64M | -6.24M | -5.08M |
| Net income from continuing ops | -108.03M | -78.73M | -87.97M | -144.25M | -8.35M |
| Net income applicable to common shares | - | - | - | -144.25M | -8.35M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1359.83M | 1638.04M | 1681.23M | 1740.03M | 1869.78M |
| Intangible assets | 286.53M | 339.68M | 373.13M | 408.26M | 442.32M |
| Other current assets | 28.86M | 31.89M | 8.24M | 8.08M | 8.19M |
| Total liab | 523.27M | 735.70M | 739.69M | 742.01M | 761.50M |
| Total stockholder equity | 836.56M | 902.34M | 941.54M | 998.02M | 1108.28M |
| Deferred long term liab | - | - | - | 34.75M | 55.48M |
| Other current liab | 60.43M | 75.07M | 68.23M | -7.56M | 56.10M |
| Common stock | 0.13M | 0.13M | 0.13M | 0.13M | 0.12M |
| Capital stock | 0.13M | 0.13M | 0.13M | 0.13M | 0.12M |
| Retained earnings | -433.81M | -325.78M | -247.06M | -159.09M | -14.84M |
| Other liab | - | - | - | 47.80M | 69.50M |
| Good will | 524.34M | 522.77M | 522.77M | 522.77M | 527.12M |
| Other assets | - | - | - | 5.11M | 7.17M |
| Cash | 159.62M | 367.01M | 342.49M | 263.18M | 316.83M |
| Total current liabilities | 88.30M | 301.24M | 96.30M | 89.93M | 87.23M |
| Current deferred revenue | - | 0.41M | 2.13M | 7.56M | 5.19M |
| Net debt | 312.66M | 238.32M | 269.19M | 347.75M | 295.96M |
| Short term debt | 4.78M | 204.16M | 5.61M | 6.65M | 8.02M |
| Short long term debt | - | 200.78M | - | - | - |
| Short long term debt total | 472.28M | 605.33M | 611.68M | 610.93M | 612.79M |
| Other stockholder equity | 1270.23M | 1228.20M | 1190.14M | 1160.88M | 1123.63M |
| Property plant equipment | - | - | - | 102.50M | 211.66M |
| Total current assets | 376.29M | 596.02M | 596.81M | 605.29M | 681.51M |
| Long term investments | - | - | - | - | 0.00M |
| Net tangible assets | - | - | - | 67.00M | 138.84M |
| Short term investments | 0.00M | 19.83M | 72.72M | 174.81M | 198.56M |
| Net receivables | 159.24M | 150.54M | 131.23M | 119.71M | 112.13M |
| Long term debt | 341.86M | 340.33M | 538.20M | 535.32M | 532.48M |
| Inventory | 28.57M | 26.75M | 24.16M | 24.28M | 23.39M |
| Accounts payable | 23.09M | 21.61M | 20.33M | 83.28M | 17.92M |
| Accumulated other comprehensive income | 0.00M | -0.21M | -1.67M | -3.90M | -0.64M |
| Common stock total equity | - | - | - | 0.13M | 0.12M |
| Retained earnings total equity | - | - | - | -159.09M | -14.84M |
| Non currrent assets other | 9.39M | 5.89M | 4.74M | -29.64M | 7.17M |
| Non current assets total | 983.54M | 1042.02M | 1084.42M | 1134.74M | 1188.27M |
| Capital lease obligations | 67.60M | 64.22M | 73.48M | 75.61M | 80.31M |
| Long term debt total | - | - | - | 535.32M | 532.48M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 19.56M | 12.86M | 76.71M | 0.52M | -133.82M |
| Change to liabilities | - | - | - | -13.30M | 5.15M |
| Total cashflows from investing activities | -12.34M | 12.86M | 76.71M | 0.52M | -632.37M |
| Net borrowings | -201.25M | 0.00M | 0.00M | -0.76M | 331.36M |
| Total cash from financing activities | -200.29M | 4.65M | 4.55M | 11.83M | 725.28M |
| Change to operating activities | - | - | - | -9.72M | -4.60M |
| Net income | -108.03M | -78.73M | -87.97M | -144.25M | -8.35M |
| Change in cash | -207.39M | 24.52M | 79.31M | -53.65M | 66.19M |
| Begin period cash flow | 367.01M | 342.49M | 263.18M | 316.83M | 250.63M |
| End period cash flow | 159.62M | 367.01M | 342.49M | 263.18M | 316.83M |
| Total cash from operating activities | 5.23M | 7.02M | -1.95M | -65.99M | -26.72M |
| Issuance of capital stock | 0.96M | 4.65M | 4.62M | 12.59M | 423.21M |
| Depreciation | 67.82M | 72.55M | 72.58M | 69.43M | 53.35M |
| Other cashflows from investing activities | 1.57M | - | - | 12.10M | -15.00M |
| Change to inventory | -1.54M | -2.70M | -0.45M | -1.10M | 1.63M |
| Change to account receivables | -6.18M | -19.31M | -11.52M | -7.58M | -4.69M |
| Sale purchase of stock | - | - | - | 12.59M | 15.08M |
| Other cashflows from financing activities | -200.29M | - | 76.71M | 0.52M | 305.12M |
| Change to netincome | - | - | - | 27.91M | -69.87M |
| Capital expenditures | 27.01M | 41.06M | 28.75M | 30.89M | 64.14M |
| Change receivables | - | - | - | -7.58M | -4.69M |
| Cash flows other operating | - | - | - | 0.06M | 7.69M |
| Cash and cash equivalents changes | - | - | - | -53.65M | 66.19M |
| Change in working capital | -32.09M | -32.63M | -25.49M | -31.70M | -4.60M |
| Stock based compensation | 41.32M | 33.41M | 24.63M | 24.67M | 22.46M |
| Other non cash items | 36.21M | 12.42M | 14.29M | 31.95M | 13.61M |
| Free cash flow | -21.78M | -34.04M | -30.70M | -96.88M | -90.86M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NEO NeoGenomics Inc |
0.77 4.61% |
17.46 | - | 222.22 | 3.17 | 3.01 | 3.48 | 197.80 |
| TMO Thermo Fisher Scientific Inc |
12.86 1.88% |
697.75 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.61 0.26% |
232.35 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.56 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-1.01 4.08% |
23.77 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
9490 NeoGenomics Way, Fort Myers, FL, United States, 33912
239 768 0600
2500
| Name | Title | Year Born |
|---|---|---|
| Mr. George A. Cardoza | Pres & COO of Lab Operations | 1962 |
| Ms. Kathryn B. McKenzie | Interim Chief Culture Officer, Chief Sustainability & Risk Officer | 1984 |
| Mr. Christopher Michael Smith BSc | CEO & Director | 1963 |
| Mr. Jeffrey S. Sherman M.B.A. | Chief Financial Officer | 1966 |
| Ms. Cynthia J. Dieter | Chief Accounting Officer | 1975 |
| Mr. John Mooney | Chief Technology Officer | NA |
| Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D. | Pres of Lab Operations & Chief Scientific Officer | NA |
| Charlie Eidson | Director of Investor Relations and Corp. Devel. | NA |
| Mr. Hutan Hashemi J.D. | Chief Compliance Officer | NA |
| Ms. Ali Olivio | Gen. Counsel & Corp. Sec. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.40%
Communication Services
+0.01%
Consumer Cyclical
+0.03%
Consumer Defensive
-0.34%
Energy
-0.10%
Financial Services
+0.20%
Financials
-0.31%
Healthcare
+0.82%
Industrials
+0.61%
Real Estate
-0.30%
Technology
+1.27%
Utilities
+0.15%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...